

Pilar Delgado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3175051/publications.pdf>

Version: 2024-02-01

70
papers

4,648
citations

109321

35
h-index

98798

67
g-index

73
all docs

73
docs citations

73
times ranked

6375
citing authors

#	ARTICLE	IF	CITATIONS
1	Biological Age Acceleration Is Lower in Women With Ischemic Stroke Compared to Men. <i>Stroke</i> , 2022, 53, 2320-2330.	2.0	11
2	Prevalence of hippocampal enlarged perivascular spaces in a sample of patients with hypertension and their relation with vascular risk factors and cognitive function. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 651-656.	1.9	32
3	Obstructive sleep apnea and silent cerebral infarction in hypertensive individuals. <i>Journal of Sleep Research</i> , 2018, 27, 232-239.	3.2	22
4	GRECOS Project (Genotyping Recurrence Risk of Stroke). <i>Stroke</i> , 2017, 48, 1147-1153.	2.0	23
5	Exome Sequencing and Clot Lysis Experiments Demonstrate the R458C Mutation of the Alpha Chain of Fibrinogen to be Associated with Impaired Fibrinolysis in a Family with Thrombophilia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 431-440.	2.0	6
6	Whole exome sequencing analysis reveals TRPV3 as a risk factor for cardioembolic stroke/subtitle. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1165-1771.	3.4	6
7	Microalbuminuria and the Combination of MRI Markers of Cerebral Small Vessel Disease. <i>Cerebrovascular Diseases</i> , 2016, 42, 66-72.	1.7	17
8	Dementia Rating Scale-2 normative data for middle-and older-aged Castilian speaking Spaniards. <i>Clinical Neuropsychologist</i> , 2016, 30, 1443-1456.	2.3	5
9	Combination of Thrombolysis and Statins in Acute Stroke Is Safe. <i>Stroke</i> , 2016, 47, 2870-2873.	2.0	58
10	Genetic variants in CETP increase risk of intracerebral hemorrhage. <i>Annals of Neurology</i> , 2016, 80, 730-740.	5.3	33
11	N-terminal pro-brain natriuretic peptide and subclinical brain small vessel disease. <i>Neurology</i> , 2016, 87, 2533-2539.	1.1	18
12	High daytime and nighttime ambulatory pulse pressure predict poor cognitive function and mild cognitive impairment in hypertensive individuals. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 253-263.	4.3	14
13	Identification of Plasma Biomarkers of Human Intracerebral Hemorrhage Subtypes through Microarray Technology. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 665-671.	1.6	4
14	N-glycome Profile Levels Relate to Silent Brain Infarcts in a Cohort of Hypertensives. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	3
15	Short-Term Blood Pressure Variability Relates to the Presence of Subclinical Brain Small Vessel Disease in Primary Hypertension. <i>Hypertension</i> , 2015, 66, 634-640.	2.7	72
16	Prevalence and Associated Factors of Silent Brain Infarcts in a Mediterranean Cohort of Hypertensives. <i>Hypertension</i> , 2014, 64, 658-663.	2.7	30
17	Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women. <i>Atherosclerosis</i> , 2014, 237, 811-815.	0.8	10
18	Meta-analysis of Genome-wide Association Studies Identifies 1q22 as a Susceptibility Locus for Intracerebral Hemorrhage. <i>American Journal of Human Genetics</i> , 2014, 94, 511-521.	6.2	235

#	ARTICLE	IF	CITATIONS
19	Investigating silent strokes in hypertensives: a magnetic resonance imaging study (ISSYS): rationale and protocol design. <i>BMC Neurology</i> , 2013, 13, 130.	1.8	41
20	Heritability Estimates Identify a Substantial Genetic Contribution to Risk and Outcome of Intracerebral Hemorrhage. <i>Stroke</i> , 2013, 44, 1578-1583.	2.0	88
21	Letter by Riba-Llena et al Regarding Article, "Not Listened or Not Reported Rather Than Silent Stroke". <i>Stroke</i> , 2013, 44, e42.	2.0	1
22	Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. <i>Pharmacogenomics</i> , 2013, 14, 495-504.	1.3	18
23	Burden of Risk Alleles for Hypertension Increases Risk of Intracerebral Hemorrhage. <i>Stroke</i> , 2012, 43, 2877-2883.	2.0	39
24	Lipoprotein-Associated Phospholipase A ₂ Activity Is Associated with Large-Artery Atherosclerotic Etiology and Recurrent Stroke in TIA Patients. <i>Cerebrovascular Diseases</i> , 2012, 33, 150-158.	1.7	36
25	Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients. <i>Stroke</i> , 2012, 43, 1398-1400.	2.0	13
26	<i>IL1B</i> and <i>VWF</i> Variants Are Associated With Fibrinolytic Early Recanalization in Patients With Ischemic Stroke. <i>Stroke</i> , 2012, 43, 2659-2665.	2.0	28
27	A predictive clinical "genetic model of tissue plasminogen activator" response in acute ischemic stroke. <i>Annals of Neurology</i> , 2012, 72, 716-729.	5.3	39
28	Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. <i>Atherosclerosis</i> , 2012, 220, 532-536.	0.8	14
29	Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. <i>Journal of Proteomics</i> , 2012, 75, 4758-4765.	2.4	68
30	Plasma β -Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke. <i>Neurodegenerative Diseases</i> , 2012, 10, 320-323.	1.4	41
31	VAP-1/SSAO Plasma Activity and Brain Expression in Human Hemorrhagic Stroke. <i>Cerebrovascular Diseases</i> , 2012, 33, 55-63.	1.7	41
32	MMP-2/MMP-9 Plasma Level and Brain Expression in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke. <i>Brain Pathology</i> , 2012, 22, 133-141.	4.1	73
33	Control de la presión arterial tras el ictus, ¿nos pasamos o no llegamos?. <i>Hipertension Y Riesgo Vascular</i> , 2011, 28, 1-3.	0.6	0
34	ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. <i>Neurobiology of Aging</i> , 2011, 32, 551.e13-551.e22.	3.1	22
35	Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. <i>Atherosclerosis</i> , 2011, 218, 181-187.	0.8	24
36	Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage. <i>PLoS ONE</i> , 2011, 6, e16750.	2.5	60

#	ARTICLE	IF	CITATIONS
37	Ischemic Stroke Outcome and Early Infection: Its Deleterious Effect Seems to Operate Also among Tissue Plasminogen Activator-Treated Patients. <i>European Neurology</i> , 2011, 65, 82-87.	1.4	8
38	Blood biomarkers to identify ischemic stroke etiologies. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 337-353.	0.2	1
39	Oxidative Stress After Thrombolysis-Induced Reperfusion in Human Stroke. <i>Stroke</i> , 2010, 41, 653-660.	2.0	83
40	Monitoring intracranial pressure in patients with malignant middle cerebral artery infarction: is it useful?. <i>Journal of Neurosurgery</i> , 2010, 112, 648-657.	1.6	103
41	Determinants of White Matter Hyperintensity Volume in Patients with Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2010, 19, 230-235.	1.6	42
42	KCNK17 genetic variants in ischemic stroke. <i>Atherosclerosis</i> , 2010, 208, 203-209.	0.8	22
43	Blood Biomarkers in Cardioembolic Stroke. <i>Current Cardiology Reviews</i> , 2010, 6, 194-201.	1.5	16
44	Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. <i>Thrombosis and Haemostasis</i> , 2009, 102, 759-764.	3.4	19
45	Transcranial Duplex Sonography for Monitoring Hyperacute Intracerebral Hemorrhage. <i>Stroke</i> , 2009, 40, 987-990.	2.0	55
46	Endogenous Activated Protein C Predicts Hemorrhagic Transformation and Mortality after Tissue Plasminogen Activator Treatment in Stroke Patients. <i>Cerebrovascular Diseases</i> , 2009, 28, 143-150.	1.7	23
47	Is it Time to Reassess the SITS-MOST Criteria for Thrombolysis?. <i>Stroke</i> , 2009, 40, 2568-2571.	2.0	40
48	Microbleeds Versus Macrobleeds. <i>Stroke</i> , 2009, 40, 2382-2386.	2.0	169
49	Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by β -amyloid 25-35 fragment. <i>Journal of Neuroscience Research</i> , 2009, 87, 2115-2125.	2.9	34
50	Quality of life and neurobehavioral changes in survivors of malignant middle cerebral artery infarction. <i>Journal of Neurology</i> , 2009, 256, 1126-1133.	3.6	65
51	Do Bubble Characteristics Affect Recanalization in Stroke Patients Treated with Microbubble-Enhanced Sonothrombolysis?. <i>Ultrasound in Medicine and Biology</i> , 2008, 34, 1573-1577.	1.5	53
52	Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. <i>Stroke</i> , 2008, 39, 2280-2287.	2.0	264
53	Progression of Symptomatic Intracranial Large Artery Atherosclerosis Is Associated With a Proinflammatory State and Impaired Fibrinolysis. <i>Stroke</i> , 2008, 39, 1456-1463.	2.0	89
54	Fas System Activation in Perihematomal Areas After Spontaneous Intracerebral Hemorrhage. <i>Stroke</i> , 2008, 39, 1730-1734.	2.0	39

#	ARTICLE	IF	CITATIONS
55	Response to Letter by Poppe et al. Stroke, 2008, 39, .	2.0	0
56	Speed of tPA-Induced Clot Lysis Predicts DWI Lesion Evolution in Acute Stroke. Stroke, 2007, 38, 955-960.	2.0	46
57	Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator. Stroke, 2007, 38, 1076-1078.	2.0	75
58	Patterns and Predictors of Early Risk of Recurrence After Transient Ischemic Attack With Respect to Etiologic Subtypes. Stroke, 2007, 38, 3225-3229.	2.0	204
59	Hyperglycemia during Ischemia Rapidly Accelerates Brain Damage in Stroke Patients Treated with tPA. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1616-1622.	4.3	101
60	Presurgical evaluation in refractory epilepsy secondary to meningitis or encephalitis: bilateral memory deficits often preclude surgery. Epileptic Disorders, 2007, 9, 127-133.	1.3	7
61	Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 1000-1004.	2.0	119
62	ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters, 2006, 398, 167-171.	2.1	23
63	Tandem Internal Carotid Artery/Middle Cerebral Artery Occlusion. Stroke, 2006, 37, 2301-2305.	2.0	350
64	Neuroprotection in Malignant MCA Infarction. Cerebrovascular Diseases, 2006, 21, 99-105.	1.7	7
65	Microbubble Administration Accelerates Clot Lysis During Continuous 2-MHz Ultrasound Monitoring in Stroke Patients Treated With Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 425-429.	2.0	431
66	A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke. Stroke, 2005, 36, 1415-1420.	2.0	146
67	Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol. Stroke, 2005, 36, 602-606.	2.0	128
68	Predictors of Early Arterial Reocclusion After Tissue Plasminogen Activator-Induced Recanalization in Acute Ischemic Stroke. Stroke, 2005, 36, 1452-1456.	2.0	199
69	Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage. Stroke, 2004, 35, 1316-1322.	2.0	199
70	Higher Risk of Further Vascular Events Among Transient Ischemic Attack Patients With Diffusion-Weighted Imaging Acute Ischemic Lesions. Stroke, 2004, 35, 2313-2319.	2.0	210